Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory

Table 4

Type of TB in 30 TB/HIV patients from Minsk according to the DST performed in Belarus and in Denmark, and number of active drugs in treatment regimens.

Type of TB	Minsk; (%)	Copenhagen; (%)	value	Number of active drugs initially, median (range)		Number of active drugs after 1st change of treatment regimen, median (range)
				RSPCPT	SRL	RSPCPT	SRL
DS TB	10 (33,3)	12 (40.0)	0.79	4 (4-4)	4 (4-4)	2 (2-3)	2 (2-3)
Isoniazid-resistant TB	2 (6.7)	2 (6.6)	1.00	4 (3-4)	4 (3-4)	5 (4-5)	5 (4-5)
MDR-TB	8 (26.7)	3 (10.0)	0.18	0 (0-5)	0 (0-0)	5 (1-5)	4 (1-5)
preXDR-TB	5 (16.7)	9 (30.0)	0.36	1 (0-1)	1 (0-1)	4 (1-5)	3 (1-4)
XDR-TB	5 (16.7)	4 (13.3)	1.00	0 (0-1)	0 (0-1)	3 (2-3)	3 (1-4)

In Minsk, drug-susceptibility testing (DST) was performed at the Republican Scientific and Practical Center for Pulmonology and TB, Minsk, Belarus. In Copenhagen, DST was performed at the WHO TB Supranational Reference Laboratory, Copenhagen, Denmark. DST = drug-susceptibility test. DS TB = drug-sensitive TB; Mycobacterium tuberculosis sensitive to all first-line anti-TB drugs. MDR-TB = multidrug-resistant TB; Mycobacterium tuberculosis resistant to both isoniazid and rifampicin. preXDR-TB = preextensive drug-resistant TB; Mycobacterium tuberculosis resistant to isoniazid and rifampicin and either to any fluoroquinolone or a second-line injectable agent but not to both. XDR-TB = extensive drug resistance; Mycobacterium tuberculosis resistant to isoniazid and rifampicin and to any fluoroquinolone and to at least one of three second-line injectable drugs. As reported. According to the results of combined phenotypic DST, line probe assay (LPA), and whole-genome sequencing (WGS). In case of discrepancies, the worst result was considered.